Circulating heparin-like anticoagulants: Case report and review of literature

Transfusion. 2021 Mar;61(3):968-973. doi: 10.1111/trf.16236. Epub 2020 Dec 22.

Abstract

We report a case of a 56-year-old woman with a history of idiopathic thrombocytopenic purpura (ITP) following splenectomy on mycophenolate mofetil (MMF), who developed moderate bleeding after stopping MMF. Her laboratory testing suggested the presence of an abnormal circulating heparin-like anticoagulant with demonstrable anti-Xa activity. She was initially treated with antifibrinolytic therapy and was subsequently started on MMF alongside intravenous immunoglobulin, which significantly improved her bleeding symptoms. The presence of abnormal circulating heparin-like anticoagulants is a rare cause of coagulopathy. Few cases exist in the literature, with nearly all occurring in the setting of hematologic or solid-organ malignancy. The mechanism by which these endogenous anticoagulants develop is unclear. Clinical manifestations range from mild bleeding and bruising to life-threatening hemorrhage refractory to conventional therapy. Diagnosis of a heparin-like anticoagulant is based on coagulation testing as well as exclusion of other exogenous anticoagulants, acquired inhibitors, and/or factor deficiencies.

Keywords: activated partial thromboplastin time; bleeding; coagulopathy; heparin-like anticoagulants; immunosuppression.

Publication types

  • Case Reports

MeSH terms

  • Anticoagulants / metabolism*
  • Antifibrinolytic Agents / therapeutic use
  • Blood Coagulation Disorders / complications*
  • Blood Coagulation Tests
  • Factor Xa Inhibitors / metabolism
  • Female
  • Hemorrhage / etiology
  • Heparin / metabolism*
  • Humans
  • Hypothyroidism / complications
  • Middle Aged
  • Mycophenolic Acid / administration & dosage
  • Purpura, Thrombocytopenic, Idiopathic / complications
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy
  • Purpura, Thrombocytopenic, Idiopathic / metabolism*
  • Splenectomy

Substances

  • Anticoagulants
  • Antifibrinolytic Agents
  • Factor Xa Inhibitors
  • Heparin
  • Mycophenolic Acid